SMi’s 6th annual Biomarkers Summit 2013 - Innovations in stratified medicine

Sept. 17, 2012 - PRLog -- The drive towards personalized medicine is seeing pharma move from patient stratification as a ‘nice to have’, to an essential feature of product development.   Exemplified by the success of Herceptin, biomarkers promise to transform drug discovery, clinical development and diagnostics in the R&D process.   This dynamic market, poised to reach a value of $33.3 billion by 2015, will continue to improve decision-making, clinical trial success rates and translational productivity.

Drawing on advances in genomics, translational medicine and clinical trial design, SMi’s sixth annual Biomarkers Summit held on 16th &17th January 2013 London brings you the latest developments from toxicity testing to compound screening and first-in-man studies to companion diagnostic assays, stay competitive with fresh insights from companies at the cutting edge of biopharmaceutical development. Attending will enable you to:

•   Accelerate companion diagnostics development for therapeutic indications

•   Validate and deliver biomarkers for patient selection during clinical trials

•   Implement sub-grouping in patient segmentation studies

•   Utilise revised FDA regulatory guidelines to aid product development

•   Optimise reimbursement strategies for diagnostics

•   Maximise biomarker identification using epigenetic and metabolomic insights


For more information visit http://www.smi-online.co.uk/goto/biomarkers-summit14.asp alternatively contact Farhaana Rahman on +44 0 207 827 6186 or email on frahman@smi-online.co.uk